Swiss study reveals Real-World impact of MS drug kesimpta
NCT ID NCT05285904
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 107 adults in Switzerland with relapsing multiple sclerosis who were already taking Kesimpta (ofatumumab) as part of their routine care. Researchers tracked how many patients had no signs of disease activity, including relapses, new brain lesions, or worsening disability. The goal was to see how well the drug works outside of a controlled clinical trial setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Baden, Canton of Aargau, 5405, Switzerland
-
Novartis Investigative Site
Lucerne, Canton of Lucerne, 6004, Switzerland
-
Novartis Investigative Site
Lucerne, Canton of Lucerne, 6006, Switzerland
-
Novartis Investigative Site
Sargans, Canton of St. Gallen, 7320, Switzerland
-
Novartis Investigative Site
Gland, Canton of Vaud, 1196, Switzerland
-
Novartis Investigative Site
Zurich, Canton of Zurich, 8006, Switzerland
-
Novartis Investigative Site
Zurich, CHE, 8001, Switzerland
-
Novartis Investigative Site
Basel, 4001, Switzerland
-
Novartis Investigative Site
Bern, 3010, Switzerland
-
Novartis Investigative Site
Lausanne, 1011, Switzerland
-
Novartis Investigative Site
Lucerne, 6000, Switzerland
-
Novartis Investigative Site
Lugano, 6900, Switzerland
-
Novartis Investigative Site
Zurich, 8091, Switzerland